This article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...
Read moreBe the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.
Get in touchThe first EU Joint Clinical Assessment (JCA) has moved from theory to reality, offering important lessons for pricing, market access, and evidence-generation teams. Using the tovorafenib assessment as a practical case study, this webinar will explore what the first JCA report reveals about evidence readiness, PICO alignment and uncertainty management under the new EU HTA framework.
Hosted by Paul Craddy, Charlie Hewitt & Lauren Boland
